Program
Tadalafil
Also written as “tadalafil”, “Tadalafil 20 mg” and “Cialis Tab. 5mg”.
Its studies are mostly in Erectile Dysfunction · Prostatic Hyperplasia · Hypertension, Pulmonary · Pulmonary Arterial Hypertension · Carcinoma, Non-Small-Cell Lung, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 490 open or running | phase 4since May 31, 2006 | Dec 16, 2002 | none ahead |
| Chong Kun Dang Pharmaceutical | 30 open or running | phase 3since Sep 2, 2015 | Sep 15, 2014 | none ahead |
| Pfizer | 20 open or running | phase 2since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Futura Medical Developments | 10 open or running | phase 3since Jul 26, 2021 | Jul 26, 2021 | none ahead |
| Hanmi Pharmaceutical | 10 open or running | phase 1since Sep 4, 2014 | Sep 4, 2014 | none ahead |
| lidia-larran-aga | 10 open or running | phase 3since May 6, 2020 | May 6, 2020 | none ahead |
| Sanofi | 10 open or running | phase 3since Jan 17, 2025 | Jan 17, 2025 | none ahead |
| Seattle Gummy | 11 open or running | phase 1since Feb 17, 2021 | Feb 17, 2021 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb, Gilead Sciences, nippon-shinyaku-co-ltd and icos-corporation.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Dec 16, 2002.
- Apr 1, 2013Phase 3 study in Hypertension, PulmonaryEli Lilly · NCT01824290 · 35 enrolled · United States, Austria, Belgium and more
- May 24, 2013Phase 3 study in Muscular Dystrophy, DuchenneEli Lilly · NCT01865084 · 331 enrolled · United States, Argentina, Belgium and more
- Sep 4, 2013Phase 3 study in Prostatic HyperplasiaEli Lilly · NCT01937871 · 909 enrolled · China
- Jul 17, 2014Phase 2 study in Essential HypertensionEli Lilly · NCT02194465 · 304 enrolled · United States, Canada, Puerto Rico
- Aug 20, 2014Phase 4 study in Erectile DysfunctionEli Lilly · NCT02224846 · 635 enrolled · China
- Sep 4, 2014Hanmi Pharmaceutical's first study: phase 1 study in Erectile DysfunctionNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT02239484 · 30 enrolled · Korea, Republic of
- Sep 15, 2014Chong Kun Dang Pharmaceutical's first studies: 2 phase 1 studiesNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT02247518, NCT02247505
- Nov 20, 2014Phase 1 study in Healthy VolunteersEli Lilly · NCT02300259 · 48 enrolled · United States
- Apr 28, 2015Phase 4 study in Prostatic HyperplasiaEli Lilly · NCT02431754 · 171 enrolled · Japan
- Sep 2, 2015Phase 3 study in Prostatic HyperplasiaChong Kun Dang Pharmaceutical · NCT03246880 · 455 enrolled · Korea, Republic of
- May 6, 2020lidia-larran-aga's first study: phase 3 study in Sexual Dysfunctions, PsychologicalNew to lidia-larran-agalidia-larran-aga · NCT04433559 · 80 enrolled
- Feb 17, 2021Seattle Gummy's first study: phase 1 study in Erectile DysfunctionNew to Seattle GummySeattle Gummy · NCT04762082 · 30 planned
- Jul 26, 2021Futura Medical Developments's first study: phase 3 study in Erectile DysfunctionNew to Futura Medical DevelopmentsFutura Medical Developments · NCT04984993 · 116 enrolled · United States, Bulgaria, Georgia and more
- Jan 17, 2025Sanofi's first study: phase 3 study in Erectile DysfunctionNew to SanofiSanofi · NCT06805513 · 2,212 enrolled · United States
TargetBeta
“Phosphodiesterase 5A inhibitor”ChEMBL 37, by rule
Other programs on PDE5A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sildenafilrule | Viatris | phase 4 | 74 |
Studies
All 59 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06805513Erectile Dysfunction · United States | 3 | Completed | Sanofi | Mar 2, 2026 | 2,212 |
| NCT04984993Erectile Dysfunction · United States, Bulgaria, Georgia and more | 3 | Completed | Futura Medical Developments | Jul 13, 2022 | 116 |
| NCT04762082Erectile Dysfunction | 1 | Not yet recruiting | Seattle Gummy | Aug 30, 2025 | 30 |
| NCT04433559Sexual Dysfunctions, Psychological | 3 | UNKNOWN | lidia-larran-aga | Aug 2021 | 80 |
| NCT03246880Prostatic Hyperplasia · Korea, Republic of | 3 | Completed | Chong Kun Dang Pharmaceutical | Apr 2016 | 455 |
| NCT02431754Prostatic Hyperplasia · Japan | 4 | Completed | Eli Lilly | Feb 2016 | 171 |
| NCT02300259Healthy Volunteers · United States | 1 | Completed | Eli Lilly | Apr 2015 | 48 |
| NCT02247518Healthy · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Oct 2014 | 16 |
| NCT02247505Healty Male Volunteers · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Oct 2014 | 29 |
| NCT02239484Erectile Dysfunction · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Sep 2014 | 30 |
| NCT02224846Erectile Dysfunction · China | 4 | Completed | Eli Lilly | May 2016 | 635 |
| NCT02194465Essential Hypertension · United States, Canada, Puerto Rico | 2 | Completed | Eli Lilly | Mar 2015 | 304 |
| NCT01937871Prostatic Hyperplasia · China | 3 | Completed | Eli Lilly | Dec 2015 | 909 |
| NCT01865084Muscular Dystrophy, Duchenne · United States, Argentina, Belgium and more | 3 | Terminated | Eli Lilly | Dec 2015 | 331 |
| NCT01824290Hypertension, Pulmonary · United States, Austria, Belgium and more | 3 | Completed | Eli Lilly | Mar 18, 2019 | 35 |
| NCT01484431Pulmonary Arterial Hypertension · United States, Canada, France and more | 2 | Completed | Eli Lilly | Apr 21, 2017 | 20 |
| NCT01460342Prostatic Hyperplasia · Japan, Korea, Republic of | 3 | Completed | Eli Lilly | Oct 2012 | 610 |
| NCT01352507Erectile Dysfunction · China | 4 | Completed | Eli Lilly | Jun 2012 | 383 |
| NCT01244620Pulmonary Arterial Hypertension · Singapore | 1 | Terminated | Pfizer | Dec 2010 | 16 |
| NCT01183650Prostatic Hyperplasia · Germany | 1 | Completed | Eli Lilly | Apr 2011 | 24 |
| NCT01160289Erectile Dysfunction · United States | 2 | Completed | Eli Lilly | Nov 2011 | 410 |
| NCT01152190Prostatic Hyperplasia · United States, Austria, Italy | 3 | Completed | Eli Lilly | Jul 2012 | 97 |
| NCT01139762Prostatic Hyperplasia · United States, Argentina, Belgium and more | 3 | Completed | Eli Lilly | Feb 2012 | 696 |
| NCT01130532Erectile Dysfunction · United States, Canada | 4 | Completed | Eli Lilly | Jan 2012 | 623 |
| NCT01122264Erectile Dysfunction · France, Germany, Greece and more | 4 | Completed | Eli Lilly | Jun 2011 | 770 |
| NCT01026818Erectile Dysfunction · Belgium, Canada, France and more | 4 | Completed | Eli Lilly | Oct 2012 | 583 |
| NCT00970632Prostatic Hyperplasia · Australia, Austria, Belgium and more | 3 | Completed | Eli Lilly | Jan 2011 | 511 |
| NCT00861757Prostatic Hyperplasia · Japan, Taiwan | 3 | Completed | Eli Lilly | Jun 2010 | 612 |
| NCT00855582Erectile Dysfunction · United States, Canada, France and more | 3 | Completed | Eli Lilly | Jul 2010 | 606 |
| NCT00848081Prostatic Hyperplasia · United States, Puerto Rico | 3 | Completed | Eli Lilly | Dec 2009 | 318 |
| NCT00836693Erectile Dysfunction · Germany, Greece, Italy and more | 3 | Completed | Eli Lilly | Jan 2010 | 217 |
| NCT00833638Erectile Dysfunction · United States | 4 | Completed | Eli Lilly | Jun 2009 | 372 |
| NCT00827242Prostatic Hyperplasia · United States, Argentina, Germany and more | 3 | Completed | Eli Lilly | Nov 2009 | 325 |
| NCT00783094Prostatic Hyperplasia · Japan | 2 | Completed | Eli Lilly | Jun 2009 | 422 |
| NCT00734604Erectile Dysfunction · United States, Australia, Brazil and more | 3 | Completed | Eli Lilly | Sep 2009 | 378 |
| NCT00549302Hypertension, Pulmonary · United States, Belgium, Canada and more | 3 | Completed | Eli Lilly | Feb 2012 | 357 |
| NCT00547625Prostatic Hyperplasia · United States | 2 | Completed | Eli Lilly | 275 | |
| NCT00547599Erectile Dysfunction · Sweden | 4 | Completed | Eli Lilly | 659 | |
| NCT00547573Erectile Dysfunction · China | 3 | Completed | Eli Lilly | 367 | |
| NCT00547508Erectile Dysfunction · United States | 3 | Completed | Eli Lilly | 485 | |
| NCT00547495Erectile Dysfunction · Japan | 3 | Completed | Eli Lilly | 343 | |
| NCT00547417Erectile Dysfunction · United States | 3 | Completed | Eli Lilly | 1,933 | |
| NCT00547352Erectile Dysfunction · Korea, Republic of | 4 | Completed | Eli Lilly | 160 | |
| NCT00547287Erectile Dysfunction · Brazil | 3 | Completed | Eli Lilly | 2,760 | |
| NCT00547183Erectile Dysfunction · Germany | 3 | Completed | Eli Lilly | 298 | |
| NCT00547092Erectile Dysfunction · United Kingdom | 4 | Completed | Eli Lilly | 386 | |
| NCT00540124Prostatic Hyperplasia · Korea, Republic of | 2 | Completed | Eli Lilly | Jun 2008 | 151 |
| NCT00422734Erectile Dysfunction · United States, Austria, France and more | 3 | Completed | Eli Lilly | Jan 2008 | 342 |
| NCT00422578Erectile Dysfunction · Finland | 4 | Completed | Eli Lilly | 200 | |
| NCT00421083Erectile Dysfunction · United States | 3 | Completed | Eli Lilly | 180 | |
| NCT00386009Prostatic Hyperplasia · United States, Greece, Portugal | 2 | Completed | Eli Lilly | May 2008 | 200 |
| NCT00384930Prostatic Hyperplasia · United States | 3 | Completed | Eli Lilly | Oct 2007 | 1,058 |
| NCT00382135Erectile Dysfunction · United States | 4 | Completed | Eli Lilly | 282 | |
| NCT00381732Erectile Dysfunction · United States | 3 | Completed | Eli Lilly | 280 | |
| NCT00333281Erectile Dysfunction · United States | 4 | Completed | Eli Lilly | 198 | |
| NCT00174486Erectile Dysfunction | 2 | Completed | Pfizer | 300 | |
| NCT00157326Hypertension · United States | 2 | Completed | Eli Lilly | 180 | |
| NCT00125918Hypertension, Pulmonary · United States, France, Italy | 3 | Completed | Eli Lilly | Aug 2007 | 406 |
| NCT00050609Gastroparesis · Canada | 2 | Completed | Eli Lilly | 2 |
How it is read
Names in the registry
- “tadalafil”, 45 entries
- “Tadalafil”, 25 entries
- “Tadalafil 20 mg”, 2 entries
- “Cialis Tab. 5mg”, 2 entries
- “Tadalafil 5 mg”, 2 entries
Conditions, from the studies’ own filings
- Erectile Dysfunction, 32 studies
- Prostatic Hyperplasia, 18 studies
- Hypertension, Pulmonary, 4 studies
- Pulmonary Arterial Hypertension, 4 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.